Twist Bioscience reports Q2 revenue increase of 27.7%, despite negative net margin and ROE.
Twist Bioscience, a synthetic DNA manufacturer, holds a "Moderate Buy" rating from eight analysts with an average one-year price target of $51.63. Price targets have been raised by firms like TD Cowen ($65) and Goldman Sachs ($55). Despite a negative net margin of 74.63% and return on equity of -32.17%, the company reported a 27.7% revenue increase in Q2, totaling $81.5 million. Insider sales have occurred, with significant institutional investments noted.
October 05, 2024
8 Articles